DE69521517T2 - Prodrug-oligonukleotide - Google Patents
Prodrug-oligonukleotideInfo
- Publication number
- DE69521517T2 DE69521517T2 DE69521517T DE69521517T DE69521517T2 DE 69521517 T2 DE69521517 T2 DE 69521517T2 DE 69521517 T DE69521517 T DE 69521517T DE 69521517 T DE69521517 T DE 69521517T DE 69521517 T2 DE69521517 T2 DE 69521517T2
- Authority
- DE
- Germany
- Prior art keywords
- prodrug
- phosphate
- derivatized
- nucleotide
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 125000003636 chemical group Chemical group 0.000 abstract 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30213294A | 1994-09-07 | 1994-09-07 | |
PCT/US1995/011477 WO1996007392A2 (en) | 1994-09-07 | 1995-09-07 | Oligonucleotide prodrugs |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69521517D1 DE69521517D1 (de) | 2001-08-02 |
DE69521517T2 true DE69521517T2 (de) | 2002-04-18 |
Family
ID=23166398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69521517T Expired - Lifetime DE69521517T2 (de) | 1994-09-07 | 1995-09-07 | Prodrug-oligonukleotide |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0779893B1 (de) |
JP (1) | JPH10505094A (de) |
AT (1) | ATE202569T1 (de) |
AU (1) | AU3675195A (de) |
CA (1) | CA2199464A1 (de) |
DE (1) | DE69521517T2 (de) |
WO (1) | WO1996007392A2 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849905A (en) * | 1994-11-23 | 1998-12-15 | Centre National De La Recherche Scientifique | Biologically active phosphotriester-type nucleosides and methods for preparing same |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US7875733B2 (en) | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
AU4156197A (en) * | 1996-08-21 | 1998-03-06 | Hybridon, Inc. | Oligonucleotide prodrugs |
AU4089397A (en) * | 1996-08-26 | 1998-03-19 | Hybridon, Inc. | Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages |
US6489304B2 (en) * | 1997-05-01 | 2002-12-03 | Hybridon, Inc. | Hyperstructure-forming carriers |
WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
SI2056845T1 (en) | 2006-08-08 | 2018-02-28 | Rheinische Friedrich-Wilhelms-Universitaet Bonn | STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES |
EP1935434A1 (de) * | 2006-12-19 | 2008-06-25 | Novosom AG | Konstruktion und Verwendung von transfektionsverstärkenden Elementen |
US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
CN102307889A (zh) * | 2008-12-23 | 2012-01-04 | 集润德斯股份公司 | 硫化剂及其用于寡核苷酸合成的用途 |
SG177564A1 (en) * | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
AU2015255202B2 (en) * | 2009-07-06 | 2017-07-27 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods of use thereof |
WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
EP2734208B1 (de) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Verfahren zur synthese von funktionalisierten nukleinsäuren |
KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
EP2872485B1 (de) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetrische hilfsgruppe |
WO2014010718A1 (ja) | 2012-07-13 | 2014-01-16 | 株式会社新日本科学 | キラル核酸アジュバント |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
JP6065263B2 (ja) * | 2012-10-25 | 2017-01-25 | 学校法人神奈川大学 | プロドラッグ化合物、オリゴヌクレオチド型プロドラッグ化合物の合成用試薬、及びオリゴヌクレオチド型プロドラッグ化合物の製造方法 |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
AU2015207773B2 (en) | 2014-01-16 | 2021-06-17 | Wave Life Sciences Ltd. | Chiral design |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547569A (en) * | 1982-11-24 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Intercalating agents specifying nucleotides |
US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
FR2705099B1 (fr) * | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
-
1995
- 1995-09-07 DE DE69521517T patent/DE69521517T2/de not_active Expired - Lifetime
- 1995-09-07 WO PCT/US1995/011477 patent/WO1996007392A2/en active IP Right Grant
- 1995-09-07 AT AT95934409T patent/ATE202569T1/de not_active IP Right Cessation
- 1995-09-07 AU AU36751/95A patent/AU3675195A/en not_active Abandoned
- 1995-09-07 JP JP8509709A patent/JPH10505094A/ja not_active Withdrawn
- 1995-09-07 CA CA002199464A patent/CA2199464A1/en not_active Abandoned
- 1995-09-07 EP EP95934409A patent/EP0779893B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE202569T1 (de) | 2001-07-15 |
EP0779893A2 (de) | 1997-06-25 |
DE69521517D1 (de) | 2001-08-02 |
WO1996007392A3 (en) | 1996-05-17 |
CA2199464A1 (en) | 1996-03-14 |
EP0779893B1 (de) | 2001-06-27 |
JPH10505094A (ja) | 1998-05-19 |
AU3675195A (en) | 1996-03-27 |
WO1996007392A2 (en) | 1996-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69521517T2 (de) | Prodrug-oligonukleotide | |
PT775149E (pt) | Novos grupos de proteccao e a sua utilizacao num processo melhorado para a sintese de oligonucleotidos | |
EP1602725A3 (de) | Enzymatische Nukleinsäure die Abasische Nukleotide enthaltet | |
PL328639A1 (en) | Synthesis of p5' phosphoamidane oligonucleotides n3' | |
CA2278715A1 (en) | Aminooxy-modified oligonucleotides | |
AU5102299A (en) | Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages | |
EP0826034A4 (de) | Herstellung grosser genomischer dna-deletionen | |
EP0251283A3 (de) | Polymarkierte Oligonukleotid-Derivate | |
WO1997026270A3 (en) | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | |
AU6589094A (en) | 7-deazapurine modified oligonucleotides | |
MY120235A (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives | |
EP1595948A3 (de) | Träger mit einer biologischen Substanz | |
IL124593A0 (en) | Substituted aryl or heteroarylamides having retinoid-like biological activity | |
DZ2051A1 (fr) | Catalyseur et procédé de préparation d'hydrocarbures. | |
FR2715847B1 (fr) | Composition contenant des acides nucléiques, préparation et utilisations. | |
EP1329519A3 (de) | Sonde zur Diagnose einer ansteckenden Krankheit verursacht durch Staphylococcus aureus | |
ATE213019T1 (de) | Chimäre oligomere mit einer rns- spaltungsaktivität | |
AU1574100A (en) | Biological nutrient removal using "the olaopa process" | |
EP1325927A3 (de) | Synthese von Oligonukleotiden | |
FR2723950B1 (fr) | Fragments nucleotidiques capables de s'hybrider specifiquemennt a l'adnr ou arnr des rickettsia et leur utilisation comme sondes ou amorces. | |
IT1283876B1 (it) | Molecole chimeriche ribozima-snrna ad attivita' catalitica per rna a localizzazione nucleare | |
WO1995003406A3 (en) | Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens | |
CA2083377A1 (en) | Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna | |
AU5974194A (en) | Oligonucleotides with rna cleavage activity | |
ID26251A (id) | Turunan-turunan asam 2,2-dimetil 3-(2-fluoro vinil) siklopropana karboksilat, proses pembuatannya dan penggunaannya sebagai pestisida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |